ESR1 and breast carcinoma: More direct evidence of the inability of tamoxifen to inhibit ligand-independently activated ER was obtained in a study showing that Aurora kinase A upon phosphorylation of ER renders breast cancer cells less sensitive to treatment with tamoxifen (56).